SCHEMBL1243960

SCHEMBL1243960

CCOC(=O)c1cn(CC)c2cc(F)c(F)c(N)c2c1=O

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
LMNA P02545 1/20 0.51
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 2/20 0.50
FOXO1 Q12778 1/20 0.50
HTT P42858 2/20 0.49
CYP1A2 P05177 1/20 0.49
STAT3 P40763 2/20 0.47
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
P2RX7 Q99572 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25069326 0.91 KMT2A (0.49) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL1242783 0.90 LMNA (0.55) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL25069795 0.90 KMT2A (0.48) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL8112020 0.88 KDM4E (0.54) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL25069771 0.87 STAT3 (0.48) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL25069270 0.85 FOXO1 (0.65) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL25069364 0.85 FOXO1 (0.53) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL1242688 0.85 KMT2A (0.50) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL1243131 0.85 KMT2A (0.50) KMT2ALMNAALDH1A1KDM4EHPGD
SCHEMBL1344997 0.85 TSHR (0.46) KMT2ALMNAALDH1A1KDM4EFOXO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. (US) 2023-02-23 US disclosed
US-7879878-B2 such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation ASTELLAS PHARMA INC. (JP) 2011-02-01 US disclosed
US-20090124617-A1 QUINOLONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-05-14 US disclosed
US-7488739-B2 Quinolone derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-02-10 US disclosed
US-20060148806-A1 Quinolone derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2006-07-06 US disclosed
EP-1650192-A1 QUINOLONE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124617-A1 QUINOLONE DERIVATIVE OR SALT THEREOF THPO, ABL1, GMPS KMT2A 2659/4885LMNA 3380/4885ALDH1A1 2093/4885
US-20060148806-A1 Quinolone derivative or salt thereof THPO, ABL1, GMPS KMT2A 2659/4885LMNA 3380/4885ALDH1A1 2093/4885
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME DCX, NES, MCL1 KMT2A 3542/4885LMNA 2581/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.